Impact of natalizumab on patient-reported outcomes in multiple sclerosis: A longitudinal study

Health and Quality of Life Outcomes

Volumn 10, Issue , 2012, Pages

  Stephenson, Judith J ^a   Kern, David M ^a   Agarwal, Sonalee S ^b   Zeidman, Ruth ^c   Rajagopalan, Krithika ^b   Kamat, Siddhesh A ^a   Foley, John ^d  

^a HEALTHCORE INC   (United States)

^b BIOGEN   (United States)

^c Medaxial Limited   (United Kingdom)

^d Rocky Mountain Neurological Associates   (United States)

Author keywords

Cognitive function; Health related quality of life; Multiple sclerosis; Natalizumab; Patient reported outcomes

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; COGNITION; DAILY LIFE ACTIVITY; EMPLOYMENT; FATIGUE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); SELF REPORT;

EID: 84871550430     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-10-155     Document Type: Article

References (33)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002, 359(9313):1221-1231. 10.1016/S0140-6736(02)08220-X, 11955556.
2. Eklund V-A, MacDonald ML. Descriptions of persons with multiple sclerosis, with an emphasis on what is needed from psychologists. Prof Psychol Res Prac 1991, 22(4):277-284.
3. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual Life Res 2006, 15(2):259-271. 10.1007/s11136-005-0891-6, 16468081.
4. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis: comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992, 49(12):1237-1242. 10.1001/archneur.1992.00530360035014, 1449401.
5. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Freeman JA, Jenkinson C, Peto V, Thompson AJ. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosurg Psychiatry 2003, 74(6):710-714. 10.1136/jnnp.74.6.710, 1738466, 12754336.
6. Canadian Burden of Illness Study Group Burden of illness of multiple sclerosis: part II: quality of life. Can J Neurol Sci 1998, 25(1):31-38. Canadian Burden of Illness Study Group.
7. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006, 66(11):1696-1702. 10.1212/01.wnl.0000218309.01322.5c, 16769943.
8. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, . AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354(9):899-910. 10.1056/NEJMoa044397, 16510744, AFFIRM Investigators.
9. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009, 8(3):254-260. 10.1016/S1474-4422(09)70021-3, 19201654.
10. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, . SENTINEL Investigators Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354(9):911-923. 10.1056/NEJMoa044396, 16510745, SENTINEL Investigators.
11. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, . AFFIRM and SENTINEL Investigators Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007, 62(4):335-346. 10.1002/ana.21163, 17696126, AFFIRM and SENTINEL Investigators.
12. Kamat SA, Rajagopalan K, Stephenson JJ, Agarwal S. Impact of natalizumab on patient-reported outcomes on a clinical practice setting: a cross-sectional survey. Patient 2009, 2(2):105-117. 10.2165/01312067-200902020-00006, 22273086.
13. Putzki N, Yaldizli O, Tettenborn B, Diener HC. Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci 2009, 285(1-2):109-113.
14. US Food and Drug Administration Guidance for Industry Patient-reported outcome measures: use in medical product development to support labelling claims 2009, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf, US Food and Drug Administration Guidance for Industry.
15. US Food and Drug Administration Tysabri® risk minimization action plan: summary of TOUCH™ http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf, US Food and Drug Administration.
16. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34(3):220-233. 10.1097/00005650-199603000-00003, 8628042.
17. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to score version 2 of the SF-12® health survey (with a supplement documenting version 1) 2002, QualityMetric Incorporated, Lincoln, RI, 3528459, 22984850.
18. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003, 41(5):582-592.
19. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001, 124(Pt 5):962-973.
20. Hobart J, Riazi A, Lamping D, Fitzpatrick R, Thompson A. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess 2004, 8(9):iii. 1-48.
21. Goodin DS. A questionnaire to assess neurological impairment in multiple sclerosis. Mult Scler 1998, 4(5):444-451.
22. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995, 45(2):251-255. 10.1212/WNL.45.2.251, 7854521.
23. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 1999, 5(5):349-354.
24. Stewart AL, Ware JE. Measuring functioning and well-being: the medical outcomes study approach 1992, Duke University Press, Durham, NC.
25. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994, 21(1):9-14.
26. Ritvo PG, . the Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee MSQLI Multiple Sclerosis Quality of Life Inventory: a user's manual 1997, National Multiple Sclerosis Society, New York, NY, the Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee.
27. Janardhan V, Bakshi R. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Neurol 2000, 57(10):1485-1491. 10.1001/archneur.57.10.1485, 11030802.
28. Jones CA, Pohar SL, Warren S, Turpin KV, Warren KG. The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes 2008, 6:1. 10.1186/1477-7525-6-1, 2265263, 18179687.
29. Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian national population health survey. Qual Life Res 2005, 14(5):1311-1320. 10.1007/s11136-004-6640-4, 16047506.
30. Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther 2006, 28(4):445-460. 10.1016/j.clinthera.2006.04.005, 16750459.
31. Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci 2011, 32(1):83-88.
32. Belachew S, Phan-Ba R, Bartholomé E, Delvaux V, Hansen I, Calay P, Hafsi KE, Moonen G, Tshibanda L, Vokaer M. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011, 18(2):240-245. 10.1111/j.1468-1331.2010.03112.x, 20561044.
33. Kappos L, Rudick R, Polman C, O'Connor P, Vermersch P, Wiendl H, Pace A, Desgrandchamps D, Hotermans C. Rapid onset of natalizumab effect regardless of baseline disease activity in multiple sclerosis. Neurology 2010, 74(9 suppl 2):A420. P05.051.